cryptocurrency a- Top Knowledge

CITIC Securities: It is expected that the scale of personal pension will grow steadily. According to the CITIC Securities Research Report, on December 12, 2024, the Ministry of Human Resources and Social Security and other departments jointly issued the Notice on the Full Implementation of Personal Pension System, and the personal pension system will be promoted to the whole country on December 15, with emphasis on product supply and collection conditions optimized. In terms of individual pension funds, 85 index funds were added. At present, the total number of personal pension products is 941, and the performance of most products is relatively stable. The personal pension system shoulders the important mission of perfecting the multi-level and multi-pillar pension insurance system and doing a good job in pension finance. It is expected that with the continuous optimization of system design, continuous enrichment of product supply and continuous improvement of service level, the scale of personal pension is expected to grow steadily, which will also help to better play the wealth management function of the capital market and build a sound policy system of "long money and long investment".Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.Bank of Japan: Japanese companies expect consumer prices to rise by 2.3% in three years, compared with 2.3% in the previous survey; Japanese companies expect consumer prices to rise by 2.2% in five years, compared with 2.2% in the last survey.

Haitong Securities: The moderate price reduction of traditional Chinese medicine varieties continues. The domestic pharmaceutical industry is expected to set off a wave of mergers and acquisitions. Haitong Securities released a research report saying that the moderate price reduction of traditional Chinese medicine varieties continues. In 2024, the traditional Chinese medicine industry was under pressure due to the pressure of pharmacy terminal sales and inventory pressure, and it is expected to return to a good situation in the next 25 years. In addition, the continuous technological changes in the pharmaceutical industry, the development of IPO to mergers and acquisitions and the promotion of corporate governance optimization at the shareholder level are the main reasons for promoting mergers and acquisitions in the industry. In terms of fields, mergers and acquisitions are expected to occur intensively in sub-sectors such as medical devices, Chinese medicine, medical services, blood products and scientific research services.The yield of China's 10-year government bonds fell below 1.80% at the beginning of the session, hitting a new record low.Citic Jiantou Pharmaceutical's 2025 strategy: looking for new additions and integration opportunities. Citic Jiantou said that looking forward to 2025, the reform policy in the medical field has been normalized, and the most noteworthy incremental policy in the medical insurance field is to establish a diversified payment system. The medical field is about to usher in the reform of "deep water areas" such as salary system and graded diagnosis and treatment, which is in line with expectations as a whole. At the same time, the innovation of China's pharmaceutical industry has gradually stepped onto the international stage, some sub-sectors will be marginally improved, and industry integration will begin. We are optimistic about the investment opportunities in the pharmaceutical industry in 2025. It is suggested to focus on the new increase (innovation, going out to sea, marginal change) and industry integration opportunities.

The fifth district of Beijing issued a blue warning of strong winds. At present, Yanqing District, Mentougou District, Haidian District, Changping District and Fangshan District of Beijing have issued blue warnings of strong winds.Yuejiang: It is planned to sell about 40 million H shares globally through the IPO of Hong Kong stocks. It is expected to be listed on the Hong Kong Stock Exchange on December 23, and Yuejiang announced on the Hong Kong Stock Exchange on December 13 that the company plans to sell about 40 million H shares globally, with Hong Kong public offering accounting for 5% and international offering accounting for 95%. The offer price will not be higher than HK$ 20.80 per offering share, and it is currently expected to be not lower than HK$ 18.80 per offering share, with 200 shares per lot. It is expected that the shares will start trading on the Stock Exchange at 9: 00 am on Monday, December 23, 2024, Hong Kong time.The A-share financing balance hit a new high of more than 9 years, and the big consumption sector broke out. According to china securities journal, on December 12, the A-share market opened lower and went higher. At the close, the Shanghai Composite Index rose by nearly 1%, the Shenzhen Composite Index rose by 1% and the Growth Enterprise Market Index rose by more than 1%. More than 3,500 stocks in the entire A-share market rose, with more than 150 stocks trading daily, and the big consumer sector broke out. The market turnover was 1.89 trillion yuan, which has exceeded 1 trillion yuan for 52 consecutive trading days, setting a new record for the A-share market. In terms of funds, Wind data shows that as of December 11th, the financing balance in the A-share market was 1,875.85 billion yuan, a record high of over 9 years. In the first three trading days of this week, the financing balance "increased three times in a row", with a cumulative increase of 22.579 billion yuan. Analysts believe that short-term ample liquidity and optimistic policy expectations are still the main support of the market. In the medium and long term, the A-share market is expected to continue to fluctuate upward under the dual promotion of policy expectations and economic trends.